Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study

Background: Thymoma-associated myasthenia gravis (TAMG) is a subtype of myasthenia gravis (MG) that is associated with more severe symptoms and a relatively poor prognosis. Eculizumab, an inhibitor to target human C5 component of the complement cascade, is considered a treatment option for refractor...

Full description

Bibliographic Details

Published in:	Therapeutic Advances in Neurological Disorders
Main Authors:	Lei Jin, Dingxian He, Quantao Zeng, Song Tan, Jianquan Shi, Ying Liu, Zhangyu Zou, Jie Song, Chong Yan, Xiao Huan, Yuan Wang, Lei Yang, Jianying Xi, Zongtai Wu, Ziqi Liu, Jianming Zheng, Chongbo Zhao, Xianglin Chu, Sushan Luo
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-12-01
Online Access:	https://doi.org/10.1177/17562864241309431